Targeted approaches toward understanding and treating pulmonary lymphangioleiomyomatosis (LAM).

Targeted approaches toward understanding and treating pulmonary lymphangioleiomyomatosis (LAM).
复制标题

DOI:
10.1007/s12672-012-0128-4
复制
发表时间:
2013-04
期刊:
影响因子:
3
通讯作者:
Krymskaya VP
Krymskaya VP
中科院分区:
医学2区
文献类型:
--
作者:
Hammes SR;Krymskaya VP

文献摘要

参考文献

被引文献

相似文献

Pulmonary lymphangioleiomyomatosis (LAM) is a rare disease found almost exclusively in women that is characterized by neoplastic growth of atypical smooth muscle-like cells in the lung, destruction of lung parenchyma, and obstruction of lymphatics. These processes lead to the formation of lung cysts, rupture of which results in spontaneous pneumothorax. Progression of LAM often results in loss of pulmonary function and death. LAM affects predominantly women of childbearing age and is exacerbated by pregnancy. The only proven treatment for LAM is lung transplantation, and even then LAM cells will often return to the transplanted lung. However, methodical and targeted approaches toward understanding LAM pathophysiology have led to the discovery of new potential therapeutic avenues. For example, the mutational inactivation of tumor suppressor complex genes tuberous sclerosis complex 1 (TSC1) or TSC2 has been shown to be present in lung LAM cells. These mutations occur sporadically or in association with inherited hamartoma syndrome tuberous sclerosis (TSC). Since TSC genes function as negative regulators of the mammalian target of rapamycin (mTOR), a major controller of cell growth, metabolism and survival, rapamycin analogs have recently been used to treat LAM patients with promising results. Similarly, studies focusing on the importance of estrogen in LAM progression have suggested that anti-estrogen therapy might prove to be an alternative means of treating LAM. This mini-review summarizes recent progress in understanding LAM pathophysiology, including the latest preclinical and clinical studies, and insights regarding the role of hormones in LAM.
AMP激活的蛋白激酶对ULK1(HATG1)的磷酸化将能量传感连接到线粒体。
DOI: 10.1126/science.1196371
发表时间: 2011-01-28
期刊: Science (New York, N.Y.)
影响因子: --
作者:
Egan DF;Shackelford DB;Mihaylova MM;Gelino S;Kohnz RA;Mair W;Vasquez DS;Joshi A;Gwinn DM;Taylor R;Asara JM;Fitzpatrick J;Dillin A;Viollet B;Kundu M;Hansen M;Shaw RJ
通讯作者: Shaw RJ
DOI: 10.1016/j.cancergen.2012.04.005
发表时间: 2012-05
期刊: Cancer genetics
影响因子: 1.9
作者:
Bowen JM;Cates JM;Kash S;Itani D;Gonzalez A;Huang D;Oliveira A;Bridge JA
通讯作者: Bridge JA
DOI: 10.1164/rccm.201003-0489oc
发表时间: 2010-12-01
影响因子: 24.7
作者:
Cai, Xiong;Pacheco-Rodriguez, Gustavo;Moss, Joel
通讯作者: Moss, Joel
DOI: 10.1016/j.anndiagpath.2004.12.007
发表时间: 2005-04-01
影响因子: 2
作者:
Fiore, Maria Grazia;Sanguedolce, Francesca;Ricco, Rosalia
通讯作者: Ricco, Rosalia
DOI: 10.1158/0008-5472.can-03-3609
发表时间: 2004-05-15
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
El-Hashemite, N;Zhang, HB;Kwiatkowski, DJ
通讯作者: Kwiatkowski, DJ